Shares of Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report) were down 2.8% during trading on Friday . The stock traded as low as $3.95 and last traded at $4.03. Approximately 4,748 shares changed hands during trading, an increase of 119% from the average daily volume of 2,165 shares. The stock had previously closed at $4.14.
Graybug Vision Price Performance
The business’s fifty day simple moving average is $4.32 and its two-hundred day simple moving average is $4.65. The company has a market cap of $6.32 million, a PE ratio of -0.17 and a beta of 1.20.
About Graybug Vision
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
See Also
- Five stocks we like better than Graybug Vision
- 5 discounted opportunities for dividend growth investors
- Texas Roadhouse Stock Steering for New Highs This Year
- Which Wall Street Analysts are the Most Accurate?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
